ArticleNeurochemical research2026
Sonic Hedgehog Protects Against Ischemic Brain Injury Via Modulating DRP1-Dependent Microglial Pyroptosis.
Article in Neurochemical research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundMicroglial pyroptosis plays a critical role in the neuroinflammation following ischemic stroke. Although Sonic Hedgehog (SHH) signaling has been shown to exert neuroprotective effects in cerebral ischemia, whether SHH regulates microglial pyroptosis and the underlying mechanisms remain largely unclear.
methodsSerum samples from patients with acute ischemic stroke (AIS) and healthy controls were analyzed using ELISA. Middle cerebral artery occlusion/reperfusion (MCAO/R) mice and oxygen-glucose deprivation/reoxygenation (OGD/R)-treated BV2 microglia were established as in vivo and in vitro ischemic models, respectively. SHH and DRP1 expression were manipulated using adeno-associated virus (AAV)-mediated knockdown or siRNA transfection. Pyroptosis-related molecules were evaluated by qRT-PCR, western blotting, immunofluorescence staining, and scanning electron microscopy. Infarct volume and neurological function were assessed by TTC staining, modified neurological severity score (mNSS), and corner test.
resultsSerum SHH levels were significantly reduced in AIS patients and negatively correlated with circulating inflammatory cytokines. Separately, GEPIA2 analysis of human brain tissue datasets revealed that SHH expression was negatively correlated with the pyroptosis-related genes IL1B, GSDMD, and CASP1. Both in vivo and in vitro ischemic interventions markedly upregulated the expression of SHH, DRP1, and pyroptosis-associated proteins in microglia. SHH knockdown elevated DRP1 expression, aggravated microglial pyroptosis, enlarged cerebral infarct volume, and worsened neurological dysfunction. Rescue experiments confirmed that DRP1 knockdown effectively reversed the pro-pyroptotic and injury-aggravating effects of SHH inhibition in microglia after ischemic stroke.
conclusionsSHH protects against cerebral ischemic injury by suppressing DRP1-mediated microglial pyroptosis. The SHH-DRP1 signaling axis represents a previously unrecognized regulatory pathway involved in ischemic stroke and may serve as a potential therapeutic target for limiting neuroinflammation and improving neurological outcomes.
Indexed as
Identifiers
42831992What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.